Laigo Bio’s SureTAC™ membrane protein degradation technology targets key signaling molecules in autoimmune, graft rejection, and oncology UTRECHT, the Netherlands - 4 December 2025 (08:30 CET). Laigo ...
Researchers say this is the first combination therapy that targets two different cancer survival mechanism: PARP and WNT signaling.
They discovered that a gene called VGLL1 (vestigial like family member 1) was turned on very early during placenta formation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback